BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Memento EPFL// BEGIN:VEVENT SUMMARY:U.S. DOD CDMRP – Breast cancer research program DTSTART;VALUE=DATE:20220617 DTSTAMP:20260408T050734Z UID:dd703898e0a7237126ae4a948930f73959a3bb248adf489e51035163 CATEGORIES:Call for proposal DESCRIPTION:Through the Congressionally Directed Medical Research Program (CDMRP)\, the Department of Defense is announcing the breast Cancer Resear ch Program (KCRP) Awards. Five award programs are available:\n \n\n The F Y22 innovator Award supports visionary individuals who have demonstrated e xceptional creativity\, innovative work\, and paradigm-shifting leadership in any field including\, but not limited to\, breast cancer. The Innovato r Award will provide these individuals with the funding and freedom to pur sue their most novel\, visionary\, high-risk ideas that could accelerate p rogress to ending breast cancer. Experience in breast cancer research is n ot required\; however\, the application must focus on breast cancer\, and the PI must maintain a 50% dedication of their full-time effort during the award period to breast cancer research. Because the intent of the Innovat or Award mechanism is to recognize these remarkably creative and innovativ e visionary individuals\, rather than projects\, the central feature of th e award is the innovative contribution that the Principal Investigator (PI ) can make toward ending breast cancer.\n FY22 Breakthrough Award - Levels 1 and 2 – supports promising research that has high potential to lead t o or make breakthroughs in breast cancer. The critical components of this award mechanism are:\n \n Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress t oward ending breast cancer.\n Research Scope: The Breakthrough Award is s tructured with four different funding levels. The levels are designed to s upport major (but not all) stages of research that will lead to clinical a pplication.\n \n Funding Level 1: Innovative\, high-risk/high-reward re search that is in the earliest stages of idea development or is an unteste d theory that addresses an important problem. To foster research that yiel ds new avenues of investigation\, preliminary data are not required. Proof of concept is the anticipated outcome.\n Funding Level 2: Research that is already supported by substantial preliminary or published data and str ongly validates clinical translation in a well-defined context within the breast cancer landscape.\n \n \n \n \n FY22 Breakthrough Award - Level 3 -  Advanced translational studies with a high degree of project readines s. Where relevant\, proof of availability of and access to necessary data\ , human samples\, cohort(s) and/or critical reagents must be provided.\n F Y22 Breakthrough Award - Level 4 - Large-scale projects that will transfor m and revolutionize the clinical management and/or prevention of breast ca ncer. Human clinical trials are required. PIs are expected to have experie nce in successfully leading large-scale projects and demonstrated ability (through personal experience or via a commitment from a collaborating clin ical investigator) to implement a clinical project successfully..\n FY22 B reast Cancer Research Program -- Era of Hope Scholar Award supports indivi duals early in their careers who have demonstrated significant potential t o effect meaningful change in breast cancer. These individuals should be e xceptionally talented scientists who have shown that they are the “best and brightest” in their field(s) through extraordinary creativity\, visi on\, innovation\, and productivity. They should have demonstrated experien ce in forming effective partnerships and collaborations and must exhibit s trong potential for future leadership in breast cancer research.\n\n\nAREA S OF INTEREST (Concept and Idea Development Award)\n\nConsidering the curr ent breast cancer landscape and the BCRP’s mission\, all FY22 BCRP Award applications must address at least one of the following overarching chall enges:\n\n Prevent breast cancer (primary prevention)\n Identify determina nts of breast cancer initiation\, risk\, or susceptibility\n Distinguish d eadly from non-deadly breast cancers\n Conquer the problems of overdiagnos is and overtreatment\n Identify what drives breast cancer growth\; determi ne how to stop it\n Identify why some breast cancers become metastatic\n D etermine why/how breast cancer cells lie dormant for years and then re-eme rge\; determine how to prevent lethal recurrence\n Revolutionize treatment regimens by replacing them with ones that are more effective\, less toxic \, and impact survival\n Eliminate the mortality associated with metastati c breast cancer.\n\n\nDEADLINE:\n\n\n FY22 Innovator Award - Pre-Applicati on (1 page limit): Aug. 3\, 2022\, submission on Nov. 2\, 2022\n FY22 Brea kthrough Award -- Levels 1 and 2 - Pre-Application (1 page limit): Sept. 2 2\, 2022\, submission on Oct. 6\, 2022\n FY22 Breakthrough Award -- Level 3 - Pre-Application: Aug. 3\, 2022\, submission on Nov. 2\, 2022\n FY22 Br eakthrough Award -- Level 4 - Pre-Application: Aug. 3\, 2022\, submission on Nov. 2\, 2022\n FY22 Breast Cancer Research Program -- Era of Hope Scho lar Award- Pre-Application: Sept. 22\, 2022\, submission on Oct 6\, 2022\n \nFUNDING:\n\n\n FY22 Innovator Award - Anticipated direct costs will not exceed $7M for a maximum of 4 year period of performance\n FY22 Breakthrou gh Award -- Levels 1 and 2 - Anticipated direct costs will not exceed $450 \,000 for a maximum of 3 years period of performance for funding level 1/s ingle PI\, $750\,000 for 3 years period of performance for funding level 1 /partnering PI\, $1M for 3 years for funding level 2/single PI and $1.5M f or 4 years for funding level 2/partnering PI\n FY22 Breakthrough Award -- Level 3 - Anticipated direct costs will not exceed $4M for a maximum of 4 years period of performance for a single PI\, $5M for 4 years with partner ing PI option.\n FY22 Breakthrough Award - Level 4 - Anticipated direct co sts will not exceed $10M for a maximum of 4 years period of performance.\n FY22 Breast Cancer Research Program -- Era of Hope Scholar Award - Antici pated direct costs will not exceed $3M for a maximum of 4 years period of performance.\n\n\nELIGIBILITY: EPFL researchers are eligible.\nHOW TO APPL Y: Pre-applications are submitted through the eBRAP platform. Full applica tions will be made via a Grants.gov workspace. Full application packages c an be downloaded from Grants.gov at any time.\nFOR FURTHER INFORMATION: Pl ease refer to the FOAs below and feel free to contact the Research Office for any question or any help.\n\n\n FY22 Innovator Award - W81XWH-22-BCRP- INNOV-2\n FY22 Breakthrough Award - Levels 1 and 2 - W81XWH-22-BCRP-BTA12- 2\n FY22 Breakthrough Award - Levels 3 - W81XWH-22-BCRP-BTA3-2\n FY22 Brea kthrough Award - Levels 4 - W81XWH-22-BCRP-BTA4-2\n FY22 Breast Cancer Res earch Program - Era of Hope Scholar Award - W81XWH-22-BCRP-EOHS-2\n\n\n\n   LOCATION: STATUS:CONFIRMED END:VEVENT END:VCALENDAR